Today's Market Winners and Losers

The stock market is down Monday, with the Dow Jones Industrial Average down 0.13%, the Nasdaq down 0.50% and the S&P 500 down 0.18%. Monday's winners include a payments company getting bought out and a technology licensing company having its patents protected. Meanwhile, Monday's losers are both pharmaceutical companies, with one throwing out the studies of a lung cancer drug and another receiving scrutiny from the federal goverment.

These are Monday's market winners and losers.

Biggest Winners

Shares of LML Payment Systems Inc. (NASDAQ: LMLP) are up 81.82% to $3.40 on trading volume of 3.9 million shares. Digital River Inc. (NASDAQ: DRIV) is buying the payments company for $3.45 a share, or about $97.3 million. Before Monday, the 52-week high was $3.33.

Shares of  Rambus Inc. (NASDAQ: RMBS) are up 22.52% to $6.04 on trading volume of 2.9 million shares. The technology licensing company was found to have destroyed potential evidence in a patent case with a South Korean semiconductor company, but the judge nevertheless believes the patents should remain valid. The 52-week high is $18.55.

Biggest Losers

Shares of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) are down 74.66% to $1.36 on trading volume of 43.2 million shares. The pharmaceutical company announced Monday that it threw out the results of a study for a lung cancer drug due to "major discrepancies" in the way the study was carried out. The 52-week low is 39 cents.

Shares of Questor Pharmaceuticals, Inc (NASDAQ: QCOR) are down 31.23% to $20.72 on trading volume of 15.6 million shares. The drug company announced Monday that its promotional practices are currently being investigated by the U.S. government. Before Monday, the 52-week low was $22.26.

Samuel Weigley

Follow him on Twitter: SWeigley

Filed under: 24/7 Wall St. Wire Tagged: DRIV, LMLP, PPHM, QCOR, RMBS
Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.